Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)

Benedetto Vitiello, Howard B. Abikoff, Shirley Z. Chuang, Scott H. Kollins, James T. McCracken, Mark A Riddle, James M. Swanson, Tim Wigal, James J. McGough, Jaswinder K. Ghuman, Sharon B. Wigal, Anne M. Skrobala, Mark Davies, Kelly Posner, Charles Cunningham, Laurence L. Greenhill

Research output: Contribution to journalArticle

Abstract

Objective: The aim of this study was to examine immediate-release methylphenidate effectiveness during the 10-month open-label continuation phase of the Preschoolers with attention-deficit/hyperactivity disorder (ADHD) Treatment Study (PATS). Methods: One hundred and forty preschoolers with ADHD, who had improved with acute immediate-release methylphenidate (IR-MPH) treatment, entered a 10-month, open-label medication maintenance at six sites. Assessments included the Clinical Global Impression-Severity (CGI-S), CGI-Improvement (CGI-I), Children's Global Assessment Scale (C-GAS), Swanson, Nolan, and Pelham Questionnaire (SNAP), Scale Strengths and Weaknesses of ADHD-Symptoms and Normal Behaviors (SWAN), Social Competence Scale, Social Skills Rating System (SSRS), and Parenting Stress Index-Short Form (PSI-SF). Results: For the 95 children who completed the 10-month treatment, improvement occurred on the CGI-S (p = 0.02), CGI-I (p <0.01), C-GAS (p = 0.001), and SSRS (p = 0.01). SNAP and SWAN scores remained stable. Forty five children discontinued: 7 for adverse effects, 7 for behavior worsening, 7 for switching to long-acting stimulants, 3 for inadequate benefit, and 21 for other reasons. The mean MPH dose increased from 14.04 mg/day ± SD 7.57 (0.71 ± 0.38 mg/kg per day) at month 1 to 19.98 mg/day ± 9.56 (0.92 ± 0.40 mg/kg per day) at month 10. Conclusions: With careful monitoring and gradual medication dose increase, most preschoolers with ADHD maintained improvement during long-term IR-MPH treatment. There was substantial variability in effective and tolerated dosing.

Original languageEnglish (US)
Pages (from-to)593-603
Number of pages11
JournalJournal of Child and Adolescent Psychopharmacology
Volume17
Issue number5
DOIs
StatePublished - Nov 1 2007

Fingerprint

Methylphenidate
Attention Deficit Disorder with Hyperactivity
Parenting
Therapeutics
Maintenance
Social Skills
Surveys and Questionnaires

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). / Vitiello, Benedetto; Abikoff, Howard B.; Chuang, Shirley Z.; Kollins, Scott H.; McCracken, James T.; Riddle, Mark A; Swanson, James M.; Wigal, Tim; McGough, James J.; Ghuman, Jaswinder K.; Wigal, Sharon B.; Skrobala, Anne M.; Davies, Mark; Posner, Kelly; Cunningham, Charles; Greenhill, Laurence L.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 17, No. 5, 01.11.2007, p. 593-603.

Research output: Contribution to journalArticle

Vitiello, B, Abikoff, HB, Chuang, SZ, Kollins, SH, McCracken, JT, Riddle, MA, Swanson, JM, Wigal, T, McGough, JJ, Ghuman, JK, Wigal, SB, Skrobala, AM, Davies, M, Posner, K, Cunningham, C & Greenhill, LL 2007, 'Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)', Journal of Child and Adolescent Psychopharmacology, vol. 17, no. 5, pp. 593-603. https://doi.org/10.1089/cap.2007.0058
Vitiello, Benedetto ; Abikoff, Howard B. ; Chuang, Shirley Z. ; Kollins, Scott H. ; McCracken, James T. ; Riddle, Mark A ; Swanson, James M. ; Wigal, Tim ; McGough, James J. ; Ghuman, Jaswinder K. ; Wigal, Sharon B. ; Skrobala, Anne M. ; Davies, Mark ; Posner, Kelly ; Cunningham, Charles ; Greenhill, Laurence L. / Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). In: Journal of Child and Adolescent Psychopharmacology. 2007 ; Vol. 17, No. 5. pp. 593-603.
@article{cb521ed5f1b449fea847f28347a63c5c,
title = "Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)",
abstract = "Objective: The aim of this study was to examine immediate-release methylphenidate effectiveness during the 10-month open-label continuation phase of the Preschoolers with attention-deficit/hyperactivity disorder (ADHD) Treatment Study (PATS). Methods: One hundred and forty preschoolers with ADHD, who had improved with acute immediate-release methylphenidate (IR-MPH) treatment, entered a 10-month, open-label medication maintenance at six sites. Assessments included the Clinical Global Impression-Severity (CGI-S), CGI-Improvement (CGI-I), Children's Global Assessment Scale (C-GAS), Swanson, Nolan, and Pelham Questionnaire (SNAP), Scale Strengths and Weaknesses of ADHD-Symptoms and Normal Behaviors (SWAN), Social Competence Scale, Social Skills Rating System (SSRS), and Parenting Stress Index-Short Form (PSI-SF). Results: For the 95 children who completed the 10-month treatment, improvement occurred on the CGI-S (p = 0.02), CGI-I (p <0.01), C-GAS (p = 0.001), and SSRS (p = 0.01). SNAP and SWAN scores remained stable. Forty five children discontinued: 7 for adverse effects, 7 for behavior worsening, 7 for switching to long-acting stimulants, 3 for inadequate benefit, and 21 for other reasons. The mean MPH dose increased from 14.04 mg/day ± SD 7.57 (0.71 ± 0.38 mg/kg per day) at month 1 to 19.98 mg/day ± 9.56 (0.92 ± 0.40 mg/kg per day) at month 10. Conclusions: With careful monitoring and gradual medication dose increase, most preschoolers with ADHD maintained improvement during long-term IR-MPH treatment. There was substantial variability in effective and tolerated dosing.",
author = "Benedetto Vitiello and Abikoff, {Howard B.} and Chuang, {Shirley Z.} and Kollins, {Scott H.} and McCracken, {James T.} and Riddle, {Mark A} and Swanson, {James M.} and Tim Wigal and McGough, {James J.} and Ghuman, {Jaswinder K.} and Wigal, {Sharon B.} and Skrobala, {Anne M.} and Mark Davies and Kelly Posner and Charles Cunningham and Greenhill, {Laurence L.}",
year = "2007",
month = "11",
day = "1",
doi = "10.1089/cap.2007.0058",
language = "English (US)",
volume = "17",
pages = "593--603",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)

AU - Vitiello, Benedetto

AU - Abikoff, Howard B.

AU - Chuang, Shirley Z.

AU - Kollins, Scott H.

AU - McCracken, James T.

AU - Riddle, Mark A

AU - Swanson, James M.

AU - Wigal, Tim

AU - McGough, James J.

AU - Ghuman, Jaswinder K.

AU - Wigal, Sharon B.

AU - Skrobala, Anne M.

AU - Davies, Mark

AU - Posner, Kelly

AU - Cunningham, Charles

AU - Greenhill, Laurence L.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Objective: The aim of this study was to examine immediate-release methylphenidate effectiveness during the 10-month open-label continuation phase of the Preschoolers with attention-deficit/hyperactivity disorder (ADHD) Treatment Study (PATS). Methods: One hundred and forty preschoolers with ADHD, who had improved with acute immediate-release methylphenidate (IR-MPH) treatment, entered a 10-month, open-label medication maintenance at six sites. Assessments included the Clinical Global Impression-Severity (CGI-S), CGI-Improvement (CGI-I), Children's Global Assessment Scale (C-GAS), Swanson, Nolan, and Pelham Questionnaire (SNAP), Scale Strengths and Weaknesses of ADHD-Symptoms and Normal Behaviors (SWAN), Social Competence Scale, Social Skills Rating System (SSRS), and Parenting Stress Index-Short Form (PSI-SF). Results: For the 95 children who completed the 10-month treatment, improvement occurred on the CGI-S (p = 0.02), CGI-I (p <0.01), C-GAS (p = 0.001), and SSRS (p = 0.01). SNAP and SWAN scores remained stable. Forty five children discontinued: 7 for adverse effects, 7 for behavior worsening, 7 for switching to long-acting stimulants, 3 for inadequate benefit, and 21 for other reasons. The mean MPH dose increased from 14.04 mg/day ± SD 7.57 (0.71 ± 0.38 mg/kg per day) at month 1 to 19.98 mg/day ± 9.56 (0.92 ± 0.40 mg/kg per day) at month 10. Conclusions: With careful monitoring and gradual medication dose increase, most preschoolers with ADHD maintained improvement during long-term IR-MPH treatment. There was substantial variability in effective and tolerated dosing.

AB - Objective: The aim of this study was to examine immediate-release methylphenidate effectiveness during the 10-month open-label continuation phase of the Preschoolers with attention-deficit/hyperactivity disorder (ADHD) Treatment Study (PATS). Methods: One hundred and forty preschoolers with ADHD, who had improved with acute immediate-release methylphenidate (IR-MPH) treatment, entered a 10-month, open-label medication maintenance at six sites. Assessments included the Clinical Global Impression-Severity (CGI-S), CGI-Improvement (CGI-I), Children's Global Assessment Scale (C-GAS), Swanson, Nolan, and Pelham Questionnaire (SNAP), Scale Strengths and Weaknesses of ADHD-Symptoms and Normal Behaviors (SWAN), Social Competence Scale, Social Skills Rating System (SSRS), and Parenting Stress Index-Short Form (PSI-SF). Results: For the 95 children who completed the 10-month treatment, improvement occurred on the CGI-S (p = 0.02), CGI-I (p <0.01), C-GAS (p = 0.001), and SSRS (p = 0.01). SNAP and SWAN scores remained stable. Forty five children discontinued: 7 for adverse effects, 7 for behavior worsening, 7 for switching to long-acting stimulants, 3 for inadequate benefit, and 21 for other reasons. The mean MPH dose increased from 14.04 mg/day ± SD 7.57 (0.71 ± 0.38 mg/kg per day) at month 1 to 19.98 mg/day ± 9.56 (0.92 ± 0.40 mg/kg per day) at month 10. Conclusions: With careful monitoring and gradual medication dose increase, most preschoolers with ADHD maintained improvement during long-term IR-MPH treatment. There was substantial variability in effective and tolerated dosing.

UR - http://www.scopus.com/inward/record.url?scp=35848947225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848947225&partnerID=8YFLogxK

U2 - 10.1089/cap.2007.0058

DO - 10.1089/cap.2007.0058

M3 - Article

VL - 17

SP - 593

EP - 603

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 5

ER -